Cargando…
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374495/ https://www.ncbi.nlm.nih.gov/pubmed/10755397 http://dx.doi.org/10.1054/bjoc.1999.1087 |
_version_ | 1782154467155640320 |
---|---|
author | Riccardi, A Mora, O Tinelli, C Valentini, D Brugnatelli, S Spanedda, R De Paoli, A Barbarano, L Di Stasi, M Giordano, M Delfini, C Nicoletti, G Bergonzi, C Rinaldi, E Piccinini, L Ascari, E |
author_facet | Riccardi, A Mora, O Tinelli, C Valentini, D Brugnatelli, S Spanedda, R De Paoli, A Barbarano, L Di Stasi, M Giordano, M Delfini, C Nicoletti, G Bergonzi, C Rinaldi, E Piccinini, L Ascari, E |
author_sort | Riccardi, A |
collection | PubMed |
description | We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57–2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2374495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23744952009-09-10 Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study Riccardi, A Mora, O Tinelli, C Valentini, D Brugnatelli, S Spanedda, R De Paoli, A Barbarano, L Di Stasi, M Giordano, M Delfini, C Nicoletti, G Bergonzi, C Rinaldi, E Piccinini, L Ascari, E Br J Cancer Regular Article We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57–2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign Nature Publishing Group 2000-04 2000-03-06 /pmc/articles/PMC2374495/ /pubmed/10755397 http://dx.doi.org/10.1054/bjoc.1999.1087 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Riccardi, A Mora, O Tinelli, C Valentini, D Brugnatelli, S Spanedda, R De Paoli, A Barbarano, L Di Stasi, M Giordano, M Delfini, C Nicoletti, G Bergonzi, C Rinaldi, E Piccinini, L Ascari, E Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title_full | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title_fullStr | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title_full_unstemmed | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title_short | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
title_sort | long-term survival of stage i multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374495/ https://www.ncbi.nlm.nih.gov/pubmed/10755397 http://dx.doi.org/10.1054/bjoc.1999.1087 |
work_keys_str_mv | AT riccardia longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT morao longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT tinellic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT valentinid longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT brugnatellis longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT spaneddar longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT depaolia longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT barbaranol longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT distasim longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT giordanom longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT delfinic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT nicolettig longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT bergonzic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT rinaldie longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT piccininil longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT ascarie longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy AT longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy |